Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma

22 May 2024

Abstract excerpt

BACKGROUND: Primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (cHL) are distinct hematological malignancies of B-cell origin that share many biological, molecular, and clinical characteristics. In particular, the JAK/STAT signaling pathway is a driver of tumor development due to multiple recurrent mutations, particularly in STAT6. Furthermore, the XPO1 gene that encodes exportin 1 (XPO1)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Heat shock proteins research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38773631
DOI: 10.1186/s13046-024-03068-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphomaPMID 38773631Read ↗

STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma.Semantic proximity Read ↗

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.Semantic proximity Read ↗

XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.Semantic proximity Read ↗

E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1Semantic proximity Read ↗

Multi-level systems analysis identifies XPO1 as a druggable target linked to NFκB activation, proliferation, tumor clonality and long-term survival in Adult T-cell LeukemiaSemantic proximity Read ↗

Protein biomarkers for response to XPO1 inhibition in haematologic malignanciesSemantic proximity Read ↗

Combining selinexor with alisertib to target the p53 pathway in neuroblastomaSemantic proximity Read ↗

The past, present, and future of CRM1/XPO1 inhibitorsSemantic proximity Read ↗

Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its InhibitorSemantic proximity Read ↗

Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition.Semantic proximity Read ↗

HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilizationSemantic proximity Read ↗

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.